8/1/2022 8:04:24 AM
Immutep Reports New Positive Interim Data From Phase II Study Of LAG-3 Candidate, Eftilagimod Alpha
7/6/2022 8:05:30 AM
Immutep Granted Japanese Patent For IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
7/6/2021 8:18:49 AM
Immutep Gets FDA And IRB Approval In The US For Phase IIb TACTI-003 Trial In Head And Neck Squamous Cell Carcinoma
6/21/2021 8:13:11 AM
Immutep Signs Agreement To Commence New Phase I Trial, Called INSIGHT-003
6/8/2021 8:16:23 AM
Immutep Provides Update On Its Preclinical Development Pipeline
4/8/2021 8:15:25 AM
Immutep Gets Fast Track Designation From FDA For Efti In First Line Recurrent/Metastatic Head & Neck Cancer